细菌性脑膜炎是一种严重的感染性疾病,随着抗生素不断问世和预防接种策略在发达国家顺利推行,在一些国家细菌性脑膜炎的病死率已降至10%左右[1~3],但是耐药菌的不断出现和临床新的抗菌药物研发速度的相对滞后,使所能选择的抗生素越来越少,仅用现有的抗生素无法达到理想的治疗效 Bacterial meningitis is a serious infectious disease. With the advent of antibiotics and vaccination strategies in developed countries, the mortality rate of bacterial meningitis in some countries has dropped to about 10% However, the continuous emergence of drug-resistant bacteria and clinical development of new anti-bacterial drug relative lag, so that fewer and fewer antibiotics can be selected, the existing antibiotics alone can not achieve the desired therapeutic effect